Valion Bio, Inc. (TIVC) Form 10-Q — May 14, 2026
Valion Bio reported a net loss of $6.2 million for the first quarter of 2026, driven by significant interest expense on its $16.25 million convertible note and operating costs associated with its new CDMO subsidiary, Velocity Bioworks. The company ended the quarter with $7.2 million in cash, which management stated raises substantial doubt about its ability to continue as a going concern within one year. The company received a formal notification from Nasdaq on March 19, 2026, stating that its common stock failed to meet the $1.00 minimum bid price requirement for continued listing.
Key figures
- Total Debt
- 16253147
- Cash Position
- 7215000
- Lease Liabilities
- 10135000
- Operating Cash Burn
- 5011000
- Shares Outstanding
- 2879857
- Accumulated Deficit
- 59034000
- Equity Line Capacity
- 50000000
- Preferred Stock Series B
- 1420000
- Preferred Stock Series C
- 6066000
- Convertible Note Principal
- 16253147
Price after filing
Close on the filing date to close N calendar days later (from $0.93). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.